Navamedic and Orion Corporation sign non-binding term sheet for Flexilev® in Europe
Oslo, 13. December 2023 - Navamedic ASA and Orion Corporation (“Orion”) have today signed a non-binding term sheet for a licensing- and supply agreement for Flexilev®, including the Orafid dispenser, across Europe, not including Sweden, Norway, Denmark, and Iceland, where Navamedic will market and sell the product. Flexilev® is a novel prescription treatment for Parkinson’s disease and was added to Navamedic’s product portfolio following the acquisition of Sensidose AB in May 2023.Orion and Navamedic have agreed to enter into a final agreement by the end of the first quarter of 2024. “